AU2002350412B2 - Abin-mediated hepatitis protection - Google Patents

Abin-mediated hepatitis protection Download PDF

Info

Publication number
AU2002350412B2
AU2002350412B2 AU2002350412A AU2002350412A AU2002350412B2 AU 2002350412 B2 AU2002350412 B2 AU 2002350412B2 AU 2002350412 A AU2002350412 A AU 2002350412A AU 2002350412 A AU2002350412 A AU 2002350412A AU 2002350412 B2 AU2002350412 B2 AU 2002350412B2
Authority
AU
Australia
Prior art keywords
tnf
abin
protein
adabin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002350412A
Other languages
English (en)
Other versions
AU2002350412A1 (en
Inventor
Rudi Beyaert
Filip Delaei
Claude Libert
Sofie Van Huffel
Ben Wielockx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of AU2002350412A1 publication Critical patent/AU2002350412A1/en
Application granted granted Critical
Publication of AU2002350412B2 publication Critical patent/AU2002350412B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
AU2002350412A 2001-06-22 2002-06-20 Abin-mediated hepatitis protection Ceased AU2002350412B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202414 2001-06-22
EP01202414.7 2001-06-22
PCT/EP2002/007154 WO2003000280A2 (en) 2001-06-22 2002-06-20 Abin-mediated hepatitis protection

Publications (2)

Publication Number Publication Date
AU2002350412A1 AU2002350412A1 (en) 2003-06-19
AU2002350412B2 true AU2002350412B2 (en) 2006-06-15

Family

ID=8180525

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002350412A Ceased AU2002350412B2 (en) 2001-06-22 2002-06-20 Abin-mediated hepatitis protection

Country Status (9)

Country Link
US (1) US7094756B2 (https=)
EP (1) EP1397154B1 (https=)
JP (1) JP4252446B2 (https=)
AT (1) ATE334696T1 (https=)
AU (1) AU2002350412B2 (https=)
CA (1) CA2447249A1 (https=)
DE (1) DE60213596T2 (https=)
ES (1) ES2269736T3 (https=)
WO (1) WO2003000280A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000280A2 (en) 2001-06-22 2003-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection
US20050147608A1 (en) * 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
JP5027508B2 (ja) 2003-09-24 2012-09-19 インスティティ・パスツール ＮＥＭＯオリゴマー化を妨害するように設計されたペプチドによるＮＦ−κＢ活性化の選択的阻害
WO2006029981A1 (en) * 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
EP1871406A1 (en) 2005-04-14 2008-01-02 VIB vzw Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
AU754434B2 (en) * 1998-05-06 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Novel inhibitors of NF-kappaB activation
WO2003000280A2 (en) 2001-06-22 2003-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection

Also Published As

Publication number Publication date
US20040136978A1 (en) 2004-07-15
JP2004536827A (ja) 2004-12-09
WO2003000280A2 (en) 2003-01-03
EP1397154B1 (en) 2006-08-02
DE60213596D1 (de) 2006-09-14
EP1397154A2 (en) 2004-03-17
ES2269736T3 (es) 2007-04-01
ATE334696T1 (de) 2006-08-15
DE60213596T2 (de) 2007-09-13
WO2003000280A3 (en) 2003-03-20
CA2447249A1 (en) 2003-01-03
US7094756B2 (en) 2006-08-22
JP4252446B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
EP2491942B1 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various cardiovascular diseases
EP2060265B1 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20020169123A1 (en) Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
CN107629114B (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
AU2002350412B2 (en) Abin-mediated hepatitis protection
EP1506784A1 (en) Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
AU2002350412A1 (en) Abin-mediated hepatitis protection
KR100739118B1 (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자의 신규한 용도
US20210179680A1 (en) Polypeptide, derivatives thereof, and application thereof in preparation of drugs having resistance to pulmonary fibrosis
US8404806B2 (en) Isolated BRCA1 peptides and method of use
US20070265201A1 (en) Inhibitors of inflammatory cytokine transcription derived from hcmv protein ie2
US7790155B2 (en) Calbindin-D28K protection against glucocorticoid induced cell death
US20110105382A1 (en) Calmodulin-binding peptides that reduce cell proliferation in cancer and smooth muscle proliferation diseases
WO2006029981A1 (en) Abin-mediated protection against lung inflammatory disease
AU2002304973B2 (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
KR20140032696A (ko) Ｖｓｉｇ４를 포함하는 간염 예방 또는 치료용 조성물
McDonald III Determinants of killer/DR5 signaling and death ligand sensitivity
HK1175102B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various cardiovascular diseases
HK1150305B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
HK1174839B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
HK1186988B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various autoimmune diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired